0001104659-14-066967.txt : 20140918 0001104659-14-066967.hdr.sgml : 20140918 20140918084528 ACCESSION NUMBER: 0001104659-14-066967 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20140918 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140918 DATE AS OF CHANGE: 20140918 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OvaScience, Inc. CENTRAL INDEX KEY: 0001544227 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 451472564 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35890 FILM NUMBER: 141109224 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-500-2802 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 a14-21085_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 18, 2014

 

OvaScience, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-35890

 

45-1472564

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

215 First Street, Suite 240

Cambridge, Massachusetts

 

02142

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (617) 500-2802

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 17, 2014, the Board of Directors of OvaScience, Inc. (the “Company”) appointed Jeffrey E. Young as the Company’s Chief Financial Officer and Treasurer. On September 18, 2014, the Company issued a press release announcing Mr. Young’s appointment, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Mr. Young, 41, has served as the Chief Financial Officer and Treasurer of TransMedics, Inc., a medical device company focused on developing and commercializing a proprietary system to enable transplantation of thoracic and other functioning organs, since August 2013. Prior to joining TransMedics, Mr. Young worked at Lantheus Medical Imaging, Inc., a developer, manufacturer and distributor of diagnostic imaging agents that provide medical imaging solutions to treat human disease, where he was the Chief Financial Officer and Treasurer from January 2012 through August 2013 and the Chief Accounting Officer, Vice President of Finance and Assistant Treasurer from September 2008 until January 2012.  Mr. Young is a certified public accountant and holds a B.S. from Georgetown University.

 

The Company and Mr. Young entered into an offer letter, dated July 22, 2014 (the “Offer Letter”), and Mr. Young’s appointment as Chief Financial Officer and Treasurer was first announced on September 18, 2014. Pursuant to the Offer Letter, Mr. Young will receive an initial annual base salary of $315,000. Mr. Young is also eligible to receive an annual discretionary bonus award of up to 35% of his current base salary. The bonus award, if any, will be determined by the Company’s Board of Directors (the “Board”) or a committee thereof and will be based upon the achievement of specific goals, which shall be determined by the Company’s Chief Executive Officer in consultation with the Board.  In connection with his appointment, Mr. Young received a stock option to purchase 224,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at an exercise price of $15.67 per share, which was the closing price of the Company’s Common Stock on the NASDAQ Global Market on September 17, 2014, the date of grant of the stock option. The stock option will have a ten-year term, vest over four years with 25% of the shares vesting on the first anniversary of Mr. Young’s start date and 6.25% of the shares vesting each quarter thereafter. In the event of a change of control (as defined in the Offer Letter) of the Company where Mr. Young’s employment is terminated by the Company without cause (as defined in the Offer Letter) or Mr. Young resigns for good reason (as defined in the Offer Letter) within one year of the change of control, the vesting of the stock options will accelerate in full.  This stock option was granted outside of the Company’s 2012 Stock Incentive Plan as an inducement material to Mr. Young’s acceptance of employment in accordance with NASDAQ Listing Rule 5635(c)(4).  As a condition of employment, Mr. Young has entered into an Invention and Non-Disclosure Agreement and a Non-Competition and Non-Solicitation Agreement with the Company. As of September 17, 2014, Mr. Young replaced Christopher Bleck as the Company’s Principal Accounting Officer and Principal Financial Officer.

 

Under the terms of the Offer Letter, Mr. Young’s employment with the Company may be terminated at any time, with or without cause and without any prior notice, by either Mr. Young or the Company. If the Company terminates Mr. Young’s employment without cause or Mr. Young terminates his employment for good reason, he will be entitled to receive (a) continuation of his then-current base salary for a period of six months (the “Severance Period”), which will be payable in periodic installments over the same period and (b) continuation of COBRA health insurance premiums at the Company’s then-normal rate of contribution during the Severance Period.  If Mr. Young commences similar employment during the Severance Period, he may no longer be entitled to receive the payments set forth above.

 

The foregoing is a summary description of the terms and conditions of the Offer Letter and is qualified in its entirety by reference to the Offer Letter, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

 

There are no family relationships between Mr. Young and any director or executive officer of the Company that are required to be disclosed pursuant to Item 401(d) of Regulation S-K. In addition, there are no transactions between the Company and Mr. Young, or any member of Mr. Young’s immediate family, that are required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

2



 

Item 9.01. Financial Statements and Exhibits

 

(d)                                 Exhibits

 

10.1                        Offer Letter dated July 22, 2014.

99.1                        Press Release dated September 18, 2014.

 

3



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

OVASCIENCE, INC.

 

 

 

 

Date: September 18, 2014

/s/ Michelle Dipp

 

Michelle Dipp, M.D., Ph.D.

 

President and Chief Executive Officer

 

4


EX-10.1 2 a14-21085_1ex10d1.htm EX-10.1

Exhibit 10.1

 

GRAPHIC

 

July 22, 2014

 

Jeffrey E. Young

516 Central Avenue

Needham, MA

02494

 

Dear Jeffrey:

 

On behalf of OvaScience, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer.

 

1.                            Employment. You will be employed, effective on a mutually agreed upon date in September 2014, to serve on a full-time basis as Chief Financial Officer of the Company. In this role, you will initially report to the Company’s Chief Executive Officer, and have such duties and responsibilities as are customary for such position, and as are otherwise assigned to you from time to time by the Company. You agree to devote your full business time, best efforts, skill, knowledge, attention, and energies to the advancement of the Company’s business and interests and to the performance of your duties and responsibilities as an employee of the Company and not to engage in any other business activities without prior approval from the Company.

 

2.                            Compensation. Your base salary will be $26,250.00 per month ($315,000 on an annualized basis), subject to applicable taxes and withholdings and may be reviewed yearly at the sole discretion of the Board. Please note that the annualized amount of your salary as described above is set forth as a matter of convenience, and shall not constitute or be interpreted as an agreement by the Company to employ you for any specific period of time. In addition to your base salary, you will be eligible to receive an annual discretionary bonus award of up to 35% of your then current base salary. The bonus award, if any, will be determined by the Board of Directors of the Company or a Committee thereof (the “Board”) in its sole discretion, based on achieving specific goals to be determined by the Chief Executive Officer of the Company in consultation with the Board. For fiscal year 2014, your annual bonus eligibility shall be prorated by .50 to reflect that you did not work a full year. To the extent that you earn any bonus hereunder, such bonus will be paid at the same time that bonuses are paid to other Company employees of similar rank and tenure, but in no event later than sixty-five (65) days following the end of the fiscal year in which it was earned. You must be an active employee of the Company on the date on which bonuses are distributed in order to be eligible for and to be deemed as having earned any bonus award.

 

3.                            Benefits. You will be eligible to participate in any and all benefit programs that the Company establishes and makes available to its employees from time to time, provided you are meet the specific eligibility criteria as set forth in (and subject to all provisions of) the plan documents governing those programs. The benefits made available by the Company, and the

 



 

rules, terms and conditions for participation in such benefit plans, may be changed by the Company at any time and from time to time without advance notice.

 

4.                                 Vacation. You will be eligible to accrue up to a maximum of twenty (20) days of paid vacation per calendar year to be taken at such times as may be approved by the Company. The number of vacation days for which you are eligible shall accrue at the rate of 1.67 days per month that you are employed during such calendar year, and shall be subject to the Company’s vacation policies and practices as in effect from time to time.

 

5.                                 Stock Options. Subject to the approval of the Board (including a majority of the independent members of the Board) or Compensation Committee, the Company will grant to you a non-qualified stock option (the “Option”) for the purchase of an aggregate of 224,000 shares of Common Stock of the Company (subject to appropriate adjustments for stock splits, stock dividends, combinations, recapitalizations and similar transactions affecting the Common Stock of the Company after the date hereof) at a price per share equal to the closing sale price of the Common Stock on the Nasdaq Global Market on the date of grant, as an inducement material to you joining the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listed Company Manual. The Option shall be subject to all terms, vesting schedules and other provisions set forth in a separate option agreement. The Option will have a term of ten (10) years except as set forth in the stock option agreement and be subject to a vesting schedule of four (4) years, with 25% of the shares vesting on the first anniversary of your employment start date and 6.25% of the shares vesting each quarter thereafter. Notwithstanding anything to the contrary in the stock option agreement, if a “Change in Control Event” (as defined on Exhibit A attached hereto) occurs and, within one (1) year of such Change in Control Event, your employment is terminated by the Company (or any successor) without “Cause” (as defined on Exhibit A) or by you for “Good Reason” (as defined on Exhibit A), the vesting schedule of the Option shall be accelerated in full. You may be eligible to receive future stock options grants as the Board shall deem appropriate and in its sole and absolute discretion.

 

6.                                 Severance Benefits Upon Termination by the Company Without “Cause” or by you for “Good Reason”. If the Company terminates your employment without Cause (as defined on Exhibit A attached hereto) or you terminate your employment for Good Reason (as defined on Exhibit A), you shall be eligible to receive the following severance benefits: (a) severance pay in an amount equal to six (6) months of your base salary as in effect at the time of your termination, payable in accordance with the Company’s regular payroll procedures proportionately over a six (6) month period following the termination of your employment (such period, the “Severance Period”); provided that, if you commence any employment substantially similar to your employment hereunder (based upon responsibility, reporting and compensation) during the Severance Period, your severance amount shall be reduced such that the number of months of severance pay to which you will be entitled shall be equal to that number of months between the date your employment with the Company terminates and the date you commence such employment; and (b) should you be eligible for and elect to continue receiving group medical and dental insurance coverage under the law known as COBRA, the Company shall continue to pay on your behalf that portion of the monthly premiums for such

 



 

coverage that it pays for active and similarly situated employees receiving the same type of coverage, through the earlier of (x) the last day of the Severance Period, or (y) the date that you become eligible for group health and/or dental insurance coverage from any new employer; provided that, if the Company determines that the payment of the premiums due under paragraph 6(b) would reasonably be expected to result in the imposition of any excise taxes on the Company for failure to comply with the nondiscrimination requirements of the Patient Protection and Affordable Care Act of 2010, as amended, (the “Act”), this payment will be treated as a taxable payment, subject to imputed income tax to the extent necessary to eliminate any discriminatory treatment or taxation under the Act. No severance pay or other benefit hereunder shall be provided to you unless, within sixty (60) days following the date that your employment is terminated, you first execute and do not revoke a separation agreement in a form prepared by and acceptable to the Company, which shall include, at a minimum, a full release of all claims against the Company (as well as its parents, subsidiaries and affiliates, and its and their, executives, officers, directors, employees, consultants, agents, shareholders, and assigns), as well as non-disparagement and confidentiality provisions in favor of the Company (the “Separation Agreement”). The severance payments shall commence on the first payroll period following the date the Separation Agreement becomes effective (the “Payment Date”). Notwithstanding the payment requirements set forth in the immediately preceding sentence, if the sixty (60) day period following the date your separation from service begins in one tax year and ends in the following tax year, the Company will commence payment on the next regular payroll date following the later of January 1 of the second tax year and the date the Separation Agreement becomes enforceable and no longer subject to revocation. The first such payment will include a catch-up payment equal to all amounts you otherwise would have received under paragraph 6(a) prior to the first payment. The distribution of any severance payments shall be subject to the provisions of Exhibit B attached hereto.

 

7.                                 Notices. Any purported termination of employment by the Company for Cause or by you for Good Reason shall be communicated to the other party through written notice, indicating the specific grounds for such termination. Such notice, and all other communications which are required or may be given pursuant to the terms of this letter, shall be sufficient in all respects if given in writing and shall be deemed given (i) if delivered personally, on the date of delivery, (ii) if mailed by certified or registered mail, return receipt requested and postage prepaid, three (3) days after the mailing date, (iii) if sent via a nationally recognized overnight courier, on the next business day thereafter, or (iv) if sent via facsimile confirmed in writing to the recipient, or via email, on the next business day thereafter, in each case, if to the Company, at the Company’s principal place of business, and if to you at the most recent home address (and/or, as applicable, the most recent personal email address) which you have provided to the Company or to such other address or addresses as either party shall have designated in writing to the other party.

 

8.                                 Invention, Non-Disclosure, Non-Competition and Non-Solicitation. As a condition of your employment with the Company, you will be required to execute an

 



 

Invention and Non-Disclosure Agreement and a Non-Competition and Non-Solicitation Agreement in the forms attached as Exhibit C and Exhibit D.

 

9.                                 Other Agreements. You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter.

 

10.                          Proof of Legal Right to Work. You agree to provide to the Company, within 3 days of your hire date, documentation of your eligibility to work in the United States, as required by the Immigration Reform and Control Act of 1986. If you need to obtain a work visa in order to be eligible to work in the United States, your employment with the Company will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company.

 

11.                          At-Will Employment. This letter shall not be construed as an agreement, either express or implied, to employ you for any stated term, and shall in no way alter the Company’s policy of employment at will, under which both you and the Company remain free to terminate the employment relationship for any reason or no reason, with or without cause, at any time, with or without notice. Similarly, nothing in this letter shall be construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company, except as explicitly set forth in paragraph 6.

 

12.                          Company Policies and Procedures. As an employee of the Company, you will be required to comply with all Company policies and procedures. Further, the Company’s premises, including all workspaces, furniture, documents and other tangible materials, and all information technology resources of the Company (including, but not limited to, computers, data and other electronic files, and all internet and e-mail systems) are subject to oversight and inspection by the Company at any time. Company employees should have no expectation of privacy with regard to any Company premises, materials, resources or information.

 

This offer letter, and the Exhibits specifically referenced herein, constitute the entire offer regarding the terms and conditions of your prospective employment with the Company. It supersedes any prior agreements, or other promises or statements (whether oral or written) regarding the offered terms of employment. The resolution of any disputes under this letter or related to your employment with or separation of employment from the Company shall be governed by Massachusetts law. By accepting this offer of employment, you agree that any action, demand, claim or counterclaim in connection with any aspect of your employment with the Company, or any separation of employment (whether voluntary or involuntary) from the Company, shall be resolved in a court of competent jurisdiction in Massachusetts by a judge alone, and you waive and forever renounce your right to a trial before a civil jury. This offer letter shall be binding upon and shall inure to the benefit of the parties and their respective successors. You shall be indemnified pursuant to any Company D&O insurance policies and/or by-laws to the same extent as similarly situated Company employees.

 



 

If this letter correctly sets forth the terms under which you will be employed by the Company, please sign the enclosed duplicate of this letter in the space provided below and return it to me or Human Resources by August 8, 2014. If you do not accept this offer by August 8, 2014, the offer will be deemed revoked.

 

 

Very truly yours,

 

 

 

OVASCIENCE, INC.

 

 

 

 

 

 

 

By:

/s/ Michelle Dipp

 

 

Michelle Dipp, M.D.,

 

 

Ph.D. Chief Executive Officer

 



 

The foregoing correctly sets forth the terms of my at-will employment with OvaScience, Inc. I am not relying on any representations other than as set forth above.

 

/s/ Jeffrey E. Young

 

Date: 8/6/2014

Jeffrey E. Young

 

 

 



 

Exhibit A

 

Definitions

 

“Cause” for termination shall be deemed to exist upon:

 

(A)                      a good faith finding by the Company (i) of failure of or refusal by the employee to perform his or her duties and responsibilities to the Company, or (ii) that the employee has engaged in dishonesty, gross negligence or misconduct, which dishonesty, gross negligence or misconduct has caused harm or damage to the business or affairs of the Company;

 

(B)                      the commission by the employee, the conviction of the employee of, or the entry of a pleading of guilty or nolo contendere by the employee to any crime involving moral turpitude or any felony; or

 

(C)                      a breach by the employee of any material provision of any invention and non-disclosure agreement or non-competition and non-solicitation agreement with the Company, which breach is not cured within ten days written notice thereof.

 

A “Change in Control Event” shall be deemed to exist upon the sale of all or substantially all of the outstanding shares of capital stock, assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other than a transaction in which all or substantially all of the individuals and entities who were beneficial owners of the capital stock of the Company immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the outstanding securities (on an as-converted to Common Stock basis) entitled to vote generally in the election of directors of the (i) resulting, surviving or acquiring corporation in such transaction in the case of a merger, consolidation or sale of outstanding shares, or (ii) acquiring corporation in the case of a sale of assets); provided that, in each of the foregoing cases, the Change in Control Event also meets all of the requirements of a “change in the ownership of a corporation” within the meaning of Treasury Regulation §1.409A-3(i)(5)(v) or “a change in the ownership of a substantial portion of the corporation’s assets” within in the meaning of Treasury Regulation §1.409A-3(i)(5)(vii).

 

“Good Reason” shall be deemed to exist upon:

 

(A)                      the relocation of the Company’s offices such that the employee’s daily commute is increased by at least forty (40) miles each way without the written consent of the employee;

 

(B)                      material reduction of the employee’s annual base salary without the prior consent of the employee (other than in connection with, and substantially proportionate to, reductions by the Company of the annual base salary of more than 50% of its employees); or

 

(C)                      material diminution in employee’s duties, authority or responsibilities without the prior consent of the employee, other than changes in duties, authority or responsibilities resulting from the employee’s misconduct; provided, however,

 



 

that (i) no such event or condition shall constitute Good Reason unless (x) the employee gives the Company a written notice of termination for Good Reason not more than 90 days after the initial existence of the condition, (y) the grounds for termination if susceptible to correction are not corrected by the Company within 30 days of its receipt of such notice and (z) the employee’s termination of employment occurs within six months following the Company’s receipt of such notice; and (ii) at all times “Good Reason” will be interpreted in a manner consistent with the definition of “good reason” within the meaning of Section 409A (as defined below).

 



 

Exhibit B

 

Payments Subject to Section 409A

 

1. Subject to this Exhibit B, payments or benefits during the Severance Period under this offer letter (“Severance Payments”) shall begin only upon the date of your “separation from service” (determined as set forth below) which occurs on or after the termination of your employment. The following rules shall apply with respect to distribution of the Severance Payments, as applicable:

 

(a)                                 It is intended that each installment of the Severance Payments shall be treated as a separate “payment” for purposes of Section 409A of the Code and the guidance issued thereunder (“Section 409A”). Neither the Company nor you shall have the right to accelerate or defer the delivery of any such Severance Payments except to the extent specifically permitted or required by Section 409A.

 

(b)                                 If, as of the date of your “separation from service” from the Company, you are not a “specified employee” (within the meaning of Section 409A), then each installment of the Severance Payments shall be made on the dates and terms set forth in the offer letter.

 

(c)                                  If, as of the date of your “separation from service” from the Company, you are a “specified employee” (within the meaning of Section 409A), then:

 

(i)                   Each installment of the Severance Payments due under the offer letter that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when your separation from service occurs, be paid within the Short-Term Deferral Period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and shall be made on the dates and terms set forth in the offer letter; and

 

(ii)                Each installment of the Severance Payments due under the offer letter that is not described in this Exhibit B, Section 1(c)(i) and that would, absent this subsection,

 



 

be paid within the six-month period following your “separation from service” from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, your death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following your separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of Severance Payments if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1 (b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-I (b)(9)(iii) must be paid no later than the last day of your second taxable year following the taxable year in which the separation from service occurs.

 

2.                                 The determination of whether and when your separation from service from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of this Exhibit B. Section 2, “Company” shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code.

 

3.                                 All expense reimbursements shall be paid as soon as administratively practicable. If an expense reimbursement or provision of in-kind benefit is not exempt from Section 409A of the Code, the following rules apply: (i) in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred; (ii) the amount of reimbursable expenses incurred or provision of in-kind benefits in one tax year shall not affect the expenses eligible for reimbursement or the provision of in-kind benefits in any other tax year; and (iii) the right to reimbursement for expenses or provision of in-kind benefits is not subject to liquidation or exchange for any other benefit.

 



 

4.                                 The Company makes no representation or warranty and shall have no liability to you or to any other person if any of the provisions of the offer letter (including this Exhibit) are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section.

 


EX-99.1 3 a14-21085_1ex99d1.htm EX-99.1

Exhibit 99.1

 

GRAPHIC

News Release

 

For Immediate Release

 

OvaScience Appoints Jeffrey Young to Chief Financial Officer

 

- Reports Inducement Option Grant under NASDAQ Rule 5635(c)(4) -

 

CAMBRIDGE, Mass., September 18, 2014 — OvaScienceSM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today the appointment of Jeffrey Young to Chief Financial Officer. Mr. Young joins OvaScience from Transmedics, Inc., where he served as Chief Financial Officer and Treasurer, leading the finance, accounting, tax and treasury functions.

 

“We are pleased to welcome Jeff to the OvaScience team.  Jeff’s experience in international finance and global operations, including the establishment of international subsidiaries and ex-U.S. revenue and tax reporting requirements, will be important to OvaScience as we expand the availability of our AUGMENT treatment and launch the OvaPrime treatment internationally next year,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer at OvaScience.

 

“This is such a pivotal time for OvaScience as the Company is transitioning to a commercial entity.  I was drawn to the Company’s mission to provide new fertility treatments to patients and to bring my experiences to help guide the expansion into new markets,” said Mr. Young.

 

Prior to serving as CFO of Transmedics, Mr. Young was CFO and Treasurer at Lantheus Medical Imaging, Inc.  While at Lantheus, an international corporation, he was responsible for multiple functions, including finance, accounting, customer service, tax and treasury. He also assisted in raising $400 million in a registered notes offering.  Before Lantheus, Mr. Young served as Chief Accounting Officer, Vice President of Finance and Treasurer at Critical Therapeutics, and managed the company’s transition during its acquisition by Cornerstone BioPharma.  Earlier in his career, Mr. Young held finance roles at PerkinElmer, Inc. and PricewaterhouseCoopers.  Mr. Young is a Certified Public Accountant and holds a B.S. in Business Administration from Georgetown University.

 

The Company also announced today the grant of an inducement option grant to Mr. Young. The award was approved by the Board’s Compensation Committee and ratified by the full Board on September 17, 2014 as an inducement material to Mr. Young’s entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

 

The inducement grant consisted of an option to purchase up to 224,000 shares of common stock.  The options will be exercisable at a price of $15.67 per share (the closing price on September 17, 2014) and will vest as to 25% of the shares on September 8, 2015, and as to an additional 6.25% of the shares per quarter thereafter, provided that he remains employed by OvaScience on the vesting date.

 



 

About OvaScience

 

OvaScience (NASDAQ: OVAS) is a global life sciences company focused on the discovery, development and commercialization of new fertility treatments.  The Company’s patented technology is based on the discovery of egg precursor cells (EggPCs), which are found in the ovaries.  By applying proprietary technology to identify and isolate EggPCSM cells, OvaScience is developing potential next generation in vitro fertilization (IVF) treatments.  OvaScience launched the AUGMENTSM treatment, which aims to improve egg quality and increase the success of IVF, in international markets and has two additional treatments in development: the OvaPrimeSM treatment, designed to boost a woman’s egg reserve using her own EggPC cells; and the OvaTureSM treatment, which seeks to create mature fertilizable eggs from a woman’s own EggPC cells without the need for hormone injections.  OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit www.ovascience.com and connect with us on Twitter and Facebook.

 

Forward-Looking Statements

 

This press release includes forward-looking statements about the Company’s plans for the AUGMENT treatment and its two fertility treatments in development, and the Company’s plans to expand the availability of the AUGMENT treatment, launch OvaPrime in 2015 internationally and transition to a commercial entity.  Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.

 

Contact:

Cara Petralia

Director, Corporate Communications

OvaScience, Inc.

cpetralia@ovascience.com

617-714-9638

 

###

 


GRAPHIC 4 g210851mmi001.jpg GRAPHIC begin 644 g210851mmi001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:JU]J%KI MT/FW4HC4G`'4L?0#O4TLJPPO*YPJ*6)]A7'QRQ74=YXAU<%[6(X@A'.['08[ M_P"-5&-S>E3BXNI4=HK^K&C)XQMXT,QL+K[.I^:4J`HJWI?BC1]7H^>TFRVB;!4Y$$"]@%S\[8_"MZ7X3:;]F;R[VX:X`^5G M"A,^X`SCZ&NF5*G'2E3LO4[ZEKS+PSJ^N>%=?3P]K@>2UF<+#( MQ+*FXX!#'^'/IM85*;@^XJ=1304445F:!1110`445Y/JNL>(/&OBJXT71 MKIK6T@9E.UR@(4X+,1R>>@K6E2=1O6R1E4J*"75L]8HKRQ_ASXKT]?M&GZ_Y MDZ\A1*Z$_B21^=>E:?\`:/[-MOM>?M'DKYN?[^!GI[T5(1BKQE<(3E+1QL6: M**BN#*MM*UNH:8(3&K'`+8X!_&LC4EHKC/`^H>+KV^O%\0VS1VZKE&>((0^> MBXZC&:[.KG#DE9LB$N=7"BBBH+"BBB@`HHHH`****`"BF22)#&9)&VJO)--A MN(;A2T,JR!3@E3G!H`J:]O\`[#O-A(/EGIZ=_P!*X'QA<-%\/=,A@8*LKDR- MSG`R",?4UZ38>*(IV\-3:-;>LL?D9*2$[=I/`Y[NF\57$=Z]MX?B;=/=RI),%/\`JX58%F/ID@`>I-7/%&@Q>(]"GL'P)<;X M7/\``XZ'^GT-73DHVY]4R*D7*_)N:%G>P7]C#>V\@>&9`ZM[&O/XO&&M^(O' M!TW1+E(=.C;YY/*5OD7[S9/J>!^%+=2T/PSJ'AMT=)C(8T8GF$$D2+_A M]37?>"O"\FB^$;B5D*ZA?P,Q]4&T[%_7/U-:NE&BFY:WT7^9DJKJM*.EM_\` M(P]:\;Z[KVN-H_A0,J*Q7S4`W28ZMD\*M2";XA>%D&H7[C4K).9X]X3V]M9S3W3JD"(3(7Z;<AK M"U?3M>\!^*)]7L(VDM979EEV[D96.2K^E2?"MHSXOO7C&V(V[E0>R[QC]*]< MCDBN(0\;I+&XX92"&%55FJ-5I+1K85*#JTTV]4]SB-!^*FE:@R0:E$=/F;C> M3NB)^O4?C^==)XD\16OAS17U&;][G"Q1J?\`6,>@SZ=\UQ_Q-\,:/;:,VKVT M,=I=+(JD1C:)LGD8]>^?8URNLR7ES\.-"DF+-'%<31ACZ?P_R84HT:=3EE'1 M-[!*M4IWC+5I;FQ97_Q!\8;KNPG^R6NXA2I$:?0'DM]:Z;PQ'XRL+B\B\03" M>W6W+PRY5OG!Z9'/3UK9\(7%I<^%-.:S*^6L"H0O\+`88'WSFM2[_P"/.?\` MZYM_*LJE6[<.5)&M.EHI,O&-Y:>&=+U;1)A$+ULG>@;C;G'/H:K7?P MXUZ_@-O>>+I;B(D$I)&S#(Z<%JR_'FCMH'@C1],>X%P8+AQY@7;G()Z?C41] ME.4=F_0I^TA&6Z7J6H+WX@^*["*ZT^1+*V"`!]P1IV'5NGC^(7>9))%BD64`LF[HP8=1S7H7A0`>$]*X_Y=8_\`T$5YY\0@/^%C:;_N MP_\`HPTJQB[.H-`6&X1R2JI_[Y`P/QJAK,D5E\8EGU(@0"XC;<_0+L`4_0'^ M5>P`@@$'(/>HDU1A'E2=U>[+BG5E*[V.,F\3ZGX7\&I=>(8Q)JK2-%''P!(> MQ.WC&.2:P;*'XC>([4:K%J2VD4@W11;O+W#V`!X^M.^,B2[M*?DQ8E'MN^7^ ME3:1X2U[4=)M;NS\:SB"6)2BJK848^[][MT_"M(J,::GHF_(B3DZCAJTO,L^ M#/%NH7VJS^&O$D2M=*&"LR@%B.JL!P>.0:[V*"&`$0Q)&#U"*!FN&TCX=WNG M^);?6KS7?MNX=<= M:"RC&6`R<[G9[B_FP99Y7+LQQTSTP. MV`*W*,C.,C-`8'H1Q6,I.3NRXQ459'(ZIX#M=2\96NM-L$`&ZYB(_P!8Z_=/ M^/T]ZZZH;NZ2RMGN)$D=4QE8T+,><<`=:FR,@9&3VIRG*25^@HQC%NW4\^\3 M?#66ZU-M5T"Z6TN';>T;$J`W]Y6'3Z5!;^`_%&KR11^)-=9[)&!:%)2Y?VZ` M?B&]I9&4>?(C2*GJH(!/YD4EB*EV]RG0IV2V/- MD^'7B76[I)/$>L@Q(>@D,C8]A@`?6N[NO#.F77AX:$\&VS5`J!3RA'1@?7/- M$GB.TBN/(:&ZWF.60#R3DB,@-@=3G(QCK5V#4+:YN)[>*3,MOM\U"""NX9'Z M43J5)6;TL$*=.-[=3S9?AWXKT2XD.@ZTHB<]I#&3]1@C-=%X6\/>)+*:\GUW M5?M9GA\J-/,9PA]><#\JZR:0PPO((VD*J2$3[S>P]ZP5\8P>7=22:5J,4=GG MSV>-<(0`ZX(JG5J5%:R)5*G3>Y0\#^"[KPI<7DMQ=PSBX50!&I&,$^OUK M-\1?#*6XU1M4T"\6TF=MYB8E0K>JL.1]*]!5E89!%&Y<9W#'3K4*O44^>^I? ML(./+;0\T7PG\0[D>3<>(?+BZ$BX8G'X#-:FK_#^ZO\`PKIVC1:BADLY&=YI M5/SDY^OK7<4C.B#+NJCKDG%-XB=TU9?(2H0L[E31K%],T:SL9'5WMX5C++T) M`QFN8\3>![O7?%%IJ\-Y#%'`(P4=22=K$UU.GZE!J44DD&X".:2$[N"2C%21 M[9%5=0UY+*^%C#8W5[<>5YKI;J#L3)`)R1U(.![5,)3C-M;E2C"44GL9OC#P M3:>*HDE\S[->Q#"3`9##^ZP[C^5G)( M'C1R"F\`[7X(]C[U%:WD=W!YRK)&NYEQ*A0Y!QT-.%><8\NZ)E1A*5]FO7%4F1G&1D=J6LYU'-W9I""@K(*X_P`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`'X'UHOM+OI='\3PI M;2%[N8F!1C,@V*,C\C74V]O#:V\=O;QK%%&H5$48"@=A4E2ZKYKH:IKELSA= M=\-30R7,6D6$BP7%C&L@B8@/()T///WMF[FI]1T>WM-7<7&ASW^F_9PEI%:C MVES<,NGPQV;W/#E MPCYX!X8';S^M/LK"2+4O,US2+N^FD2#[+.J^8L("*"IY^4A@23WKMZ*/;2>X M_8I'G^@Z1J%OK5M+?)?)>1SN9I4M5V2@Y^]+N^9<8P,<<<5Z!1145)N;NRX0 %4%9'_]D_ ` end GRAPHIC 5 g210851ks01i001.jpg GRAPHIC begin 644 g210851ks01i001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:L?5M>6Q ME%K:PFZNV./+7^'/K_A6A?7(L[&>Y./W2%N?I7'"^_L+PS<^()"&O+QB(VDY M"]?\"??BKA'F=CHIQA&G*M4U2Z=V)K/BG5-&D6.ZO;4738*V449>0@^N.GYU M7TWXKV;RF+4[22'CB2(;N?0KUJCX)\*-KL;ZKK)9HS(3M#'=.V>=[=<#I@>] M=[)XM65TDEZ$VEZO8:U:" MZT^Y2>+H2O53Z$=0:NUYE_PC]YX#\3PWUC.\NF7#@2AN6"_Q`^I`RP^AKT>. MZMY=NR>-MP!4!ASFL:D%'6+NF33FY:25FB:BBHWGAC;;)*B'T9@*R-22BH;F M[MK.(S75Q%!&/XY'"C\S45GJNG:B2+*^M[@CJ(I`Q'X"G9VN*ZO8MU0U36], MT6(2:E>Q6RM]T.>6^@ZFK4=U;S.4BGC=QU57!(KQ[3;2#QK\0[Q-8N65`TFR M,-@L%;`0'MQS6U*DIW&+B`QQ6\ULY'$DY?YC@ZGV[?(L453O-7TW3VVWE_;6[?W9)0I_(T+JV.AK/E>YI=;%E)8Y-WER*^TX;:TB,MS/'#&.KR.%'YFJG%*5HNY,)-QO)6) M:*IV>KZ;J#%+._MKAA_#'*&/Y"K+RQQ`&1U0'IN.*EIK1E)ICZ*JW6IV%C&L MEW>P0(W*F20+N^F>M+9ZA9:@A>SNX;A1U,4@;'UQ19VN%U>Q9HI"0!D]*SW\ M0Z+'-Y3ZM9J_]TSK_C0DWL#:6YHT4R.1)4$D;JZ,,AE.0:IW.N:39S>3TT^XT_`>RE;?"Y'W6],]N_YUM0DHS39T\CKX:=&/Q; MKS\CI_`NT>#M.09W+'\X/7<22<_GG\:Z"O(?"_C*ZT65;>[1)!\J.'.UY%'" MLI/&0,#![`5ZE::G;W5F;H[X(QG/GC9P._N/?I3KTY1DWW."C-./+U1#K][! MI^CS75S%YJ+A=HZDL0O'O\U>>_$3PU)HSV7B#3"RM`(XYG7J&7`1_P`<8/X5 MTTVIKXKUJWLK#=)IEG*)IK@#Y)Y%.513_=!Y)]@*Z:]LH-0L9K*Y0/#,A1U] MC3A-T6K_`#]!3BJJ?X&5HOBFSU+PJ--/ M%]WXBU-3]ALSYI4]..43\`,G_P"O6#J&G:QHVIW7A2)W=+J=-L8'$W/R']>? MI[5[%HOAR#1_#`T>,C+Q,)9!_$[#D_Y["MYJ-!-Q?Q;>AC%RK-*2^'?U/-+& MTU#XG>)IYKJY:&R@YP.1&A/RJHZ9/ MSE?W4,!W%F[9QT_&JJRJQFHTU[O3L325)P;F]>IP_P`*F>3QA>22C]XUNY?C M')<9_6MKQ7\-)[O49-5T*=8II&\QX'.WY_56[?2L3X62.WBV]ED'SM;.S#IS MO!-=UIGQ!\.:C#E[]+.4<-%<'80?KT/YTJTJD:KE#L@HJG*DE,XBU\:>+/"5 MTEIKUM)<1=A.,,1ZJXZ_CFNF\7^-TMO"%M?Z/+B34B5BD(YC`^\?J.GUK-^) M'BK0=0T'^S[2XBO;EI%96B^818/)W=.1QCWK%U7PW?)\,-,NFB?=;RR321XY M6.3H:,7=6-'PS\,X]7T^/5=3UKI]&\#6/A>>]O+&YG=9K9HS'+@X[YR,>E4O!WC[1I]$MK34+N.SNK: M,1L)3M5P!@$'IT[5T47B'2-62ZMM/OXKF6.%G<1G(`Z=>E859UN9J6QM2C1Y M4UN>?_"*1(;K6)7.$2%&8^@!:L@:A;>-?$TMSXAU466GQY,49;'RYX5??N36 MK\)X?M,FMP$X\V!4SZ9W"L'PXFCZ/XAN-.\56"O$/W>YP?W3`]>.Q']*ZVE[ M2;ZZ>IRIOV<%TU+7B73/#6EQ0ZAX7UO-Q$XS$)BR,Q_('-8GCV32YO!.D/HL7E6)N'\I= MI'8Y.#SUS40GS2CH]'NRYQY8RU6VR+GA_P"'%OK>C6NHZU?W,DLT*^4D;`") M,?*.0>U<])I]UX$\?VEO;7+.C21D-T\R-C@JP_/^=>K>%/\`D4]*_P"O2/\` M]!%>>?$/_DHVF?[L/_HPU%*K*=249/34JK3C&G&2WT+'Q`UO4=7\21>%-,D* M(65)`K8\QVYP3_=`K2M/A#HZ6H6[O+J6($9*3-L=?;!I3')/A MYJ.E0G4+2RM;Q$"S+,Q7+#N"3@@]:N+:II'1?&S MZ):WXO--N694=3\I.,JP'8]C7KM<1IK_``_M]=M(M*BMGOWX4UXTD0I(@=3U5AD&BBNF1U_&J6E?#[P[I%RMU#:-+,ARC3N7VGU`Z9HHJU4 MFERIZ$NG!N[6IH:=X8T;2;Z6^L;(17$P(=]['()R>I]:S-1^'/AK49FF:S:W M=CEC;N4!/TZ?I110JDT[I@Z<&K-"Z9\.O#>F7"SI:/<2*W9CDB"0J/RZ#\*OZ M'X0T;P_YQL('#SKLD=Y"Q*^E%%4ZLVK-Z$JG!.Z1/I'AK2-!DE?3+,6[3`!R M&8Y`Z=3[U'K?A/1?$#!]0LU>4#`E0E7Q]1U_&BBESROS7U*Y(VY;:&1#\+O# M$4@9H+B4`_=>8X_3%;-WX6T2^TZ#3Y]/C-K;',42DJ%/X&BBFZM1N[;)5*"V M1HVMK#96L5K;ILAA0(BYS@#H*S]0\,:-JFHQZA>V0EN8@H20NPQ@Y'`/K114 MJ33NF6XIJS1